Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Br J Neurosurg ; 37(4): 634-636, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31342790

RESUMEN

We report the fourth case of Carbapenem-resistant Klebsiella pneumoniae (CRKP) meningitis and the only one associated with brain abscess formation. A 29-years-old male patient developed septic shock 13 days after a right nasopharyngeal AVM resection. CRKP was grown from CSF with a MIC for meropenem ≥16 mg/L. Intravenous tigecycline and amikacin, combined with intrathecal amikacin and oral sulfamethoxazole were given. CSF culture was sterile on the 23rd day post operation. A right temporal lobe brain abscess formed by day 38 and was drained. Antibiotics were changed to oral sulfamethoxazole and minocycline for four weeks. The patient was cured with no relapse to date. With few cases reported we can only carefully recommend the combinational use of intravenous antibiotics with high dose intrathecal/intraventricular aminoglycosides.


Asunto(s)
Absceso Encefálico , Enterobacteriaceae Resistentes a los Carbapenémicos , Infección Hospitalaria , Infecciones por Klebsiella , Meningitis , Neumonía , Masculino , Humanos , Adulto , Amicacina/uso terapéutico , Infecciones por Klebsiella/tratamiento farmacológico , Infecciones por Klebsiella/complicaciones , Klebsiella pneumoniae , Infección Hospitalaria/tratamiento farmacológico , Antibacterianos/uso terapéutico , Meropenem/uso terapéutico , Meningitis/tratamiento farmacológico , Sulfametoxazol/uso terapéutico , Absceso Encefálico/diagnóstico por imagen , Absceso Encefálico/tratamiento farmacológico , Absceso Encefálico/cirugía , Pruebas de Sensibilidad Microbiana
2.
Nat Commun ; 13(1): 302, 2022 01 18.
Artículo en Inglés | MEDLINE | ID: mdl-35042848

RESUMEN

A 30-year-old bombing victim with a fracture-related pandrug-resistant Klebsiella pneumoniae infection after long-term (>700 days) antibiotic therapy is treated with a pre-adapted bacteriophage along with meropenem and colistin, followed by ceftazidime/avibactam. This salvage therapy results in objective clinical, microbiological and radiological improvement of the patient's wounds and overall condition. In support, the bacteriophage and antibiotic combination is highly effective against the patient's K. pneumoniae strain in vitro, in 7-day mature biofilms and in suspensions.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Fracturas Óseas/microbiología , Infecciones por Klebsiella/microbiología , Infecciones por Klebsiella/terapia , Klebsiella pneumoniae/fisiología , Terapia de Fagos , Adulto , Compuestos de Azabiciclo/farmacología , Compuestos de Azabiciclo/uso terapéutico , Bacteriófagos/genética , Bacteriófagos/ultraestructura , Biopelículas/efectos de los fármacos , Ceftazidima/farmacología , Ceftazidima/uso terapéutico , Islas de CpG/genética , Combinación de Medicamentos , Farmacorresistencia Microbiana/efectos de los fármacos , Farmacorresistencia Microbiana/genética , Fracturas Óseas/complicaciones , Fracturas Óseas/diagnóstico por imagen , Genoma Viral , Humanos , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/diagnóstico por imagen , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/genética , Klebsiella pneumoniae/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Polimorfismo de Nucleótido Simple/genética , Proteómica , Replicón/genética
3.
Bull Exp Biol Med ; 171(4): 458-460, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34542762

RESUMEN

High efficiency of a combined preparation including synergistic polymyxin B and 4-hexylresorcinol was shown for treatment of experimental sepsis caused by an antibiotic-resistant highly virulent hypermucoid Klebsiella pneumoniae strain KPM9Pmr in mice. Complex therapy with polymyxin B (1 mg/kg) and 4-hexylresorcinol (30 mg/kg) led to cure in 80%; in 20% of these mice, no bacterial cells were found. After treatment with polymyxin B alone, only 50% animals survived and all of them contained bacterial cells. Comparative analysis of the results of monotherapy and combined treatment indicates that 4-hexylresorcinol not only increases the efficiency of antibiotic, but also minimizes persistence of the infection agent and therefore, the risk of development of antibiotic resistance.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Hexilresorcinol/farmacología , Klebsiella pneumoniae/efectos de los fármacos , Sepsis/tratamiento farmacológico , Animales , Animales no Consanguíneos , Antibacterianos/farmacología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Femenino , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/tratamiento farmacológico , Infecciones por Klebsiella/patología , Klebsiella pneumoniae/patogenicidad , Ratones , Pruebas de Sensibilidad Microbiana , Polimixina B/farmacología , Polimixina B/uso terapéutico , Polimixinas/análogos & derivados , Polimixinas/farmacología , Polimixinas/uso terapéutico , Sepsis/microbiología
4.
J Chemother ; 32(1): 15-20, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31713469

RESUMEN

In this study, we aimed to investigate retrospectively the patients with carbapenem-resistant Enterobacteriaceae urinary tract infections (UTIs) in the terms of demographic findings, antibiotic sensitivity patterns and clinical features along with the treatment options. This study was performed at a tertiary-care educational university hospital. Adult (>18 years old) patients diagnosed with culture proven UTI due to carbapenem-resistant Klebsiella pneumoniae (between December 2016 to December 2017) were included in the study. Antimicrobial susceptibility testing of the isolates was performed with the VITEK 2 system (bioMérieux). Resistance to imipenem, ertapenem, and meropenem was tested by E-test (bioMérieux). The results were interpreted according to the EUCAST criteria. A total number of 100 patients (34% female, mean age 61.69 ± 1.65 years) were included in this study. One month all-cause mortality rate was 19%. Microbiologic eradication rate was 88.7% while it was significantly higher in combination therapy (65/70 vs. 14/19, p = 0.019) and carbapenem long-lasting (4 h) infusion subgroups (54/56 vs. 2/56, p = 0.005). Relapse and reinfection rates were 61.7 and 29.7%, respectively. Logistic regression analysis for mortality risk factors resulted as history of ertapenem usage (OR: 4.74, 95% CI: 0.678-33.201, p = 0.117), lack of microbiologic eradication (OR: 21.7, 95% CI: 1.906-247.375, p = 0.013) and ICU stay (OR: 54.8, 95% CI: 4.145-726.324, p = 0.002). Combination, carbapenem long-lasting infusion and double carbapenem therapies seem to result in higher microbiologic eradication rates and thus may effect the mortality rates of these group of patients. Randomized-controlled studies should be performed in this critical patient group to confirm these results.


Asunto(s)
Antiinfecciosos/uso terapéutico , Enterobacteriaceae Resistentes a los Carbapenémicos , Infecciones por Klebsiella/complicaciones , Infecciones Urinarias/microbiología , Proteínas Bacterianas , Farmacorresistencia Microbiana , Quimioterapia Combinada , Femenino , Humanos , Klebsiella pneumoniae , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Infecciones Urinarias/tratamiento farmacológico , beta-Lactamasas
5.
Clin Neurol Neurosurg ; 188: 105592, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31760254

RESUMEN

A 38-year-old male presented to the hospital with headache, fever, and meningeal signs. He had undergone a surgical review of a ventriculoperitoneal shunt system one month earlier. A head computed tomography scan showed hydrocephalus. His medical history included a human immunodeficiency virus infection identified four years before and resolved cryptococcal meningitis, which had necessitated the implantation of the shunt system. Ventricular cerebrospinal fluid (CSF) was obtained, which showed inflammation and, in culture, grew a Gram-negative bacillus identified as multidrug-resistant Klebsiella oxytoca. The shunt was removed and a ventricular drain was installed. Treatment with meropenem and amikacin was established without a response; the CSF white blood cell count continued to increase, with cultures remaining positive. The patient's clinical condition deteriorated to stupor. With informed consent, intraventricular (ITV) treatment with tigecycline was initiated at a dose of 5 mg every 24 h and, three days later, the CSF cultures were negativized. Tigecycline levels in the CSF were quantified by liquid chromatography with ultraviolet detection and showed peak concentrations achieved at two hours after the dose of between 178 and 310 µg/mL. After 11 days of treatment with ITV tigecycline and eight negative CSF cultures, a new CSF shunt was installed. During follow-up review 10 months later, the patient reported he was working. The dose of tigecycline used in this study produced levels 15 to 20 times the minimum inhibitory concentration of the bacteria for up to six hours with adequate tolerance.


Asunto(s)
Antibacterianos/uso terapéutico , Ventriculitis Cerebral/tratamiento farmacológico , Farmacorresistencia Bacteriana Múltiple , Infecciones por Klebsiella/tratamiento farmacológico , Infección de la Herida Quirúrgica/tratamiento farmacológico , Tigeciclina/uso terapéutico , Derivación Ventriculoperitoneal , Adulto , Antibacterianos/líquido cefalorraquídeo , Fármacos Anti-VIH/uso terapéutico , Ventriculitis Cerebral/complicaciones , Ventriculitis Cerebral/diagnóstico , Ventriculitis Cerebral/microbiología , Combinación Efavirenz, Emtricitabina y Fumarato de Tenofovir Disoproxil/uso terapéutico , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Humanos , Inyecciones Intraventriculares , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/diagnóstico , Infecciones por Klebsiella/microbiología , Klebsiella oxytoca/aislamiento & purificación , Klebsiella oxytoca/fisiología , Masculino , Pruebas de Sensibilidad Microbiana , Infección de la Herida Quirúrgica/complicaciones , Infección de la Herida Quirúrgica/diagnóstico , Infección de la Herida Quirúrgica/microbiología , Tigeciclina/líquido cefalorraquídeo
6.
Pol Merkur Lekarski ; 46(276): 251-256, 2019 Jun 28.
Artículo en Polaco | MEDLINE | ID: mdl-31260434

RESUMEN

Klebsiella pneumoniae belongs to the Enterobacteriaceae family and is responsible for 70% of human infections. From 20 to 80% strains of Klebsiella pneumoniae reveal resistance to first line antibiotics, including cephalosporins, fluoroquinolones and aminoglycosides, as well as carbapenems. Due to the resistance found in MDR (multidrug resistant) Klebsiella pneumoniae is classified according to the sequence types (ST), which are defined on the basis of the nucleotide sequence in the 7 loci (mdh, infB, tonB, gapA, phoE, pgi, and rpoB). Klebsiella pneumoniae uses several methods to protect against the effects of the human immune system. It affects receptors that recognize patterns expressed on epithelial cells and the immune system that are responsible for initiating signal cascades and phagocytic influences, including Toll-like receptors (TLRs) 2 and 4. Activates interleukins (IL) 12 (IL-12) and IL-23p40 by natural stimulation and leads to a decrease in the level of activation of interferon gamma (IFN-γ), IL-17, tumor necrosis factor (TNF-α) and IL-1ß, resulting in neutrophil and macrophage inflow and induction of humoral and cellular responses. Capsular polysaccharides and other components of the bacterial cell membrane protect it from the natural mechanisms of resistance, making it resistant to beta-defensins against bacteria. Increased virulence of Klebsiella pneumoniae is related to the protein structure associated with the capsule, especially in strains with increased virulence (HV - hypervirulent), lipopolysaccharides (LPS), siderophores and cilia (fimbriae). Today, two main types of Klebsiella pneumoniae strains are distinguished depending on the mechanism of resistance to antibiotics: strains that express beta-lactamases with extended spectrum (ESBL - extended spectrum beta-lactamases) that are resistant to cephalosporins and monobactams and strains that reveal the expression of carbapenemases, which they show resistance to available beta-lactams, including carbapenes. Polymyxins are useful in the treatment of patients infected with Klebsiella pneumoniae NDM (New Delhi metallo-beta-lactamase), where the effectiveness of therapy is greater when colistin is used together with carbapenem or rifampicin or tigecycline. The introduced abivactam in combination with ceftazidime is a promising therapeutic combination in severe infections. Similar clinical assessments were obtained with sulbactam, especially in combination with meropenem and colistin.


Asunto(s)
Infecciones por Klebsiella , Klebsiella pneumoniae , Antibacterianos , Carbapenémicos , Humanos , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/aislamiento & purificación , Pruebas de Sensibilidad Microbiana
7.
Int Urol Nephrol ; 50(1): 21-24, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29170899

RESUMEN

PURPOSE: To determine the clinical utility of preoperative urine cultures in asymptomatic men undergoing prostate needle biopsy (PNB). METHODS: One hundred fifty asymptomatic men had urine cultures obtained 14-days prior to PNB. As per study protocol, positive cultures were not treated. Antibiotic prophylaxis prior to PNB included ciprofloxacin 500 mg the night before and morning of the biopsy. Repeat urine cultures were obtained immediately prior to PNB with colony-forming units (CFUs) annotated. Infectious complications post-biopsy were recorded. RESULTS: Of the 150 men, six patients (4%) had evidence of asymptomatic bacteriuria with > 10,000 CFU/mL on office urine culture. Repeat urine cultures on morning of biopsy in all 150 patients noted a mean bacterial count of 55 CFU/mL (range 0-1000). All six patients with positive office urine cultures had < 100 CFU/mL at time of PNB. Following biopsy, four patients (2.7%) developed an infectious complication including two with sepsis and two with culture-positive UTIs. The causative organism in all cases was quinolone-resistant E. coli. None of the six patients with preoperative positive urine cultures developed an infectious complication following PNB. CONCLUSIONS: In this prospective observational study, under 5% of asymptomatic men had positive office cultures prior to PNB. Furthermore, repeat urine culture on the morning of biopsy showed resolution in these patients, and none developed post-biopsy infectious complications. Routine office urine culture in the asymptomatic male prior to PNB was unnecessary.


Asunto(s)
Antibacterianos/uso terapéutico , Profilaxis Antibiótica , Bacteriuria/diagnóstico , Ciprofloxacina/uso terapéutico , Próstata/patología , Sepsis/etiología , Infecciones Urinarias/etiología , Anciano , Enfermedades Asintomáticas , Bacteriuria/microbiología , Biopsia con Aguja/efectos adversos , Recuento de Colonia Microbiana , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/diagnóstico , Humanos , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/diagnóstico , Masculino , Persona de Mediana Edad , Periodo Preoperatorio , Estudios Prospectivos , Sepsis/microbiología , Urinálisis , Infecciones Urinarias/microbiología , Orina/microbiología
8.
Mycopathologia ; 180(3-4): 237-43, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26045285

RESUMEN

Majocchi's granuloma (MG) is a rare deep skin dermatophyte infection that can occur either in immunocompetent or in immunocompromised individuals. Oral itraconazole or terbinafine is considered to be the first choice of treatment. We report an immunocompetent man with deep nodular form of MG, the form which is generally found in immunosuppressed individuals. Previous treatment with either oral itraconazole or terbinafine yielded no apparent improvement. After a series of examination, the man was diagnosed as having Trichophyton rubrum-induced MG mixed with bacterial infection as evidenced by growth of Klebsiella pneumoniae in tissue bacterial culture. The patient was treated with a combination of cefoselis and levofloxacin for bacterial clearance followed by voriconazole treatment. After approximately 4 months of voriconazole treatment, the lesions completely resolved. Alternative medicine (voriconazole) can be considered in case of refractory infections during MG treatment.


Asunto(s)
Antifúngicos/administración & dosificación , Coinfección/tratamiento farmacológico , Granuloma/tratamiento farmacológico , Tiña/tratamiento farmacológico , Trichophyton/aislamiento & purificación , Voriconazol/administración & dosificación , Antibacterianos/administración & dosificación , Ceftizoxima/administración & dosificación , Ceftizoxima/análogos & derivados , Coinfección/complicaciones , Coinfección/patología , Granuloma/microbiología , Granuloma/patología , Humanos , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/tratamiento farmacológico , Infecciones por Klebsiella/patología , Klebsiella pneumoniae/aislamiento & purificación , Levofloxacino/administración & dosificación , Masculino , Persona de Mediana Edad , Tiña/complicaciones , Tiña/patología , Resultado del Tratamiento
9.
Fetal Pediatr Pathol ; 34(1): 18-20, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25166299

RESUMEN

Glutathione synthetase deficiency (GSSD) is a rare disorder of glutathione metabolism with varying clinical severity. Patients may present with hemolytic anemia alone or together with acidosis and central nervous system impairment. Diagnosis is made by clinical presentation and detection of elevated concentrations of 5-oxoproline in urine and low glutathione synthetase activity in erythrocytes or cultured skin fibroblasts. The prognosis seems to depend on early diagnosis and treatment. We report a 4 months old Tunisian male infant who presented with severe metabolic acidosis with high anion gap and hemolytic anemia. High level of 5-oxoproline was detected in her urine and diagnosis of GSSD was made. Treatment consists of the correction of acidosis, blood transfusion, and supplementation with antioxidants. He died of severe metabolic acidosis and sepsis at the age of 15 months.


Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/diagnóstico , Anemia Hemolítica/diagnóstico , Glutatión Sintasa/deficiencia , Glutatión Sintasa/orina , Ácido Pirrolidona Carboxílico/orina , Acidosis/complicaciones , Errores Innatos del Metabolismo de los Aminoácidos/complicaciones , Anemia Hemolítica/complicaciones , Antioxidantes/química , Eritrocitos/enzimología , Resultado Fatal , Fiebre/complicaciones , Fibroblastos/enzimología , Humanos , Lactante , Infecciones por Klebsiella/complicaciones , Masculino , Sepsis/complicaciones , Piel/citología , Resultado del Tratamiento , Túnez
10.
Am J Emerg Med ; 33(2): 222-8, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25498529

RESUMEN

OBJECTIVES: The objectives were to investigate the clinical characteristics of community-onset bacteremia in cirrhotic adults visiting the emergency department (ED), as well as the clinical impact of empirical antibiotics on their outcome. METHODS: Cirrhotic adults with community-onset bacteremia who visited the ED from January 2005 to December 2009 were included retrospectively. Clinical data and outcome were collected from the medical chart. The in vitro susceptibility was measured by the broth microdilution method. RESULTS: Of the 246 bacteremic episodes in cirrhotic patients, the major sources of bacteremia included intraabdominal infections (111, 45.1%), primary bacteremia (43, 17.5%), urinary tract infection (39, 15.9%), and soft tissue infection (22, 8.9%). Of the 258 bacteremic pathogens identified, Escherichia coli (83 isolates, 33.7%) and Klebsiella pneumoniae (61, 23.6%) were the most common microorganisms. In the multivariate analysis, delayed appropriate antibiotic therapy (>72 hours; odds ratio [OR], 4.29; P=.003), serum creatinine greater than 1.5 mg/dL at the ED (OR, 3.12; P=.005), severe sepsis (OR, 3.61; P=.01), Pittsburgh bacteremia score of at least 4 (OR, 2.66; P=.04), bacteremia due to pneumonia (OR, 5.44; P=.02), and a comorbidity of diabetes mellitus (OR, 3.54; P=.004) were independently associated with the 28-day mortality. CONCLUSIONS: Focusing on cirrhotic adults with community-onset bacteremia, we emphasized that the cirrhosis severity is one of the critical factors when choosing empirical antimicrobial therapy and that the strategy of empirical therapy is warranted for cirrhotic adults with severe decompensation (Child's C group). For critically ill patients, especially in those with Child's C group, only piperacillin/tazobactam, ertapenem, or imipenem treatment was warranted because of susceptibility rate of greater than 90%.


Asunto(s)
Bacteriemia/complicaciones , Cirrosis Hepática/complicaciones , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Infecciones Comunitarias Adquiridas/complicaciones , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/microbiología , Servicio de Urgencia en Hospital/estadística & datos numéricos , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/tratamiento farmacológico , Femenino , Humanos , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae , Cirrosis Hepática/tratamiento farmacológico , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento
11.
Pan Afr Med J ; 18: 199, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25419326

RESUMEN

The tropical diabetes hand syndrome is a complication affecting patients with diabetes mellitus in the tropics, and consists of localized cellulitis, swelling and ulceration of the hands which may progress to fulminant sepsis and gangrene of the whole limb. It is associated with a poor outcome. We report a 32 year old woman with tropical diabetes hand infection with autoamputation of the digits, review the relevant literature, and highlight the need for prevention and early hospital presentation in diabetics with hand infection, in order to prevent potentially crippling or fatal complications.


Asunto(s)
Celulitis (Flemón)/etiología , Complicaciones de la Diabetes/fisiopatología , Deformidades Adquiridas de la Mano/etiología , Infecciones por Klebsiella/complicaciones , Úlcera Cutánea/etiología , Adulto , Glucemia/análisis , Celulitis (Flemón)/microbiología , Complicaciones de la Diabetes/sangre , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Humanos , Medicinas Tradicionales Africanas , Factor de Crecimiento Derivado de Plaquetas/uso terapéutico , Factores de Riesgo , Úlcera Cutánea/tratamiento farmacológico , Infección de Heridas/etiología
12.
Antimicrob Agents Chemother ; 57(11): 5394-7, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23959321

RESUMEN

Polymyxins are reserved for salvage therapy of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Though synergy has been demonstrated for the combination of polymyxins with carbapenems or tigecycline, in vitro synergy tests are nonstandardized, and the clinical effect of synergy remains unclear. This study describes outcomes for patients with CRKP infections who were treated with polymyxin B monotherapy. We retrospectively reviewed the medical records of patients with CRKP infections who received polymyxin B monotherapy from 2007 to 2011. Clinical, microbiology, and antimicrobial treatment data were collected. Risk factors for treatment failure were identified by logistic regression. Forty patients were included in the analysis. Twenty-nine of 40 (73%) patients achieved clinical cure as defined by clinician-documented improvement in signs and symptoms of infections, and 17/32 (53%) patients with follow-up culture data achieved microbiological cure. End-of-treatment mortality was 10%, and 30-day mortality was 28%. In a multivariate analysis, baseline renal insufficiency was associated with a 6.0-fold increase in clinical failure after adjusting for septic shock (odds ratio [OR] = 6.0; 95% confidence interval [CI] = 1.22 to 29.59). Breakthrough infections with organisms intrinsically resistant to polymyxins occurred in 3 patients during the treatment. Eighteen of 40 (45%) patients developed a new CRKP infection a median of 23 days after initial polymyxin B treatment, and 3 of these 18 infections were polymyxin resistant. The clinical cure rate achieved in this retrospective study was 73% of patients with CRKP infections treated with polymyxin B monotherapy. Baseline renal insufficiency was a risk factor for treatment failure after adjusting for septic shock. Breakthrough infections with organisms intrinsically resistant to polymyxin B and development of resistance to polymyxin B in subsequent CRKP isolates are of concern.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , Polimixina B/uso terapéutico , Insuficiencia Renal Crónica/tratamiento farmacológico , Resistencia betalactámica , Adulto , Anciano , Anciano de 80 o más Años , Carbapenémicos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Femenino , Humanos , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/microbiología , Infecciones por Klebsiella/mortalidad , Klebsiella pneumoniae/crecimiento & desarrollo , Modelos Logísticos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/microbiología , Insuficiencia Renal Crónica/mortalidad , Estudios Retrospectivos , Factores de Riesgo , Análisis de Supervivencia , Insuficiencia del Tratamiento
13.
Rev Iberoam Micol ; 30(4): 261-3, 2013.
Artículo en Español | MEDLINE | ID: mdl-23318163

RESUMEN

BACKGROUND: The significant increase in systemic fungal infections is mainly due to the increase in immunocompromised patients. The high morbimortality of these infections, along with the high hospitalization costs they generate, makes them a problem of great importance in our hospital practice. Saprochaete capitata is a rare fungus that causes invasive infections, usually in immunocompromised patients, and for which there is still no consensus on the treatment regimen to be used. CASE REPORT: We present a case of disseminated infection by this fungus in a heavily immunosuppressed patient, who died as a result of multiple organ failure despite the life support measures taken and the wide spectrum antibiotics. CONCLUSIONS: It is vital to begin the antibiotic treatment as soon as possible, as well as the monitoring and follow-up cultures to test for fungi in neutropenic patients.


Asunto(s)
Antifúngicos/uso terapéutico , Dipodascus/aislamiento & purificación , Fungemia/microbiología , Insuficiencia Multiorgánica/etiología , Adulto , Antiinfecciosos/uso terapéutico , Bacteriemia/microbiología , Infecciones por Citomegalovirus/complicaciones , Diagnóstico Diferencial , Dipodascus/efectos de los fármacos , Quimioterapia Combinada , Esofagitis/virología , Resultado Fatal , Femenino , Fungemia/tratamiento farmacológico , Fungemia/etiología , Herpes Zóster/diagnóstico , Humanos , Huésped Inmunocomprometido , Infecciones por Klebsiella/complicaciones , Lupus Eritematoso Sistémico/complicaciones , Pruebas de Sensibilidad Microbiana , Neutropenia/complicaciones
14.
Urologiia ; (4): 5-7, 2012.
Artículo en Ruso | MEDLINE | ID: mdl-23116014

RESUMEN

The efficacy of phytogenic drug prolit septo in the complex treatment of patients with urolithiasis complicated by infectious-inflammatory process was evaluated. The effects of prolit septo were assessed by a comparative evaluation of the results of microbiological analysis of urine in 14 patients of main group and 12 patients of control group. Patients in both groups were matched by sex, age, and results of raiological, clinical, biochemical and microbiological methods of examination. For the treatment of 11 patients of the main group, prolit septo was applied in combination with standard anti-bacterial treatment, 3 patients received monotherapy with prolit septo within 3-6 weeks. The drug was administered at a dose of 1200 mg (2 capsules) 3 times a day. Twelve patients of the control group received only standard treatment. The duration of treatment in both groups was 1-2 weeks. It was found that combined therapy with prolit septo is more effective than standard antibacterial treatment. Against the background of combined therapy the disappearance of bacteriuria was noted in 54.5% of patients of main group compared with 8.3% of patients of control group.


Asunto(s)
Bacteriuria/tratamiento farmacológico , Enterococcus faecalis/efectos de los fármacos , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , Fitoterapia , Urolitiasis/tratamiento farmacológico , Adulto , Antibacterianos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Bacteriuria/complicaciones , Bacteriuria/diagnóstico , Creatinina/sangre , Quimioterapia Combinada , Enterococcus faecalis/fisiología , Femenino , Infecciones por Bacterias Grampositivas/complicaciones , Infecciones por Bacterias Grampositivas/diagnóstico , Humanos , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/diagnóstico , Klebsiella pneumoniae/fisiología , Masculino , Persona de Mediana Edad , Phyllanthus , Extractos Vegetales/uso terapéutico , Urolitiasis/complicaciones , Urolitiasis/diagnóstico , Adulto Joven
15.
Ophthalmology ; 119(11): 2358-63, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22817832

RESUMEN

PURPOSE: Although endophthalmitis secondary to pyogenic liver abscess (PLA) is becoming a globally emerging infectious disease, population-based investigations evaluating the relationship between PLA and endogenous endophthalmitis remain scarce. This study aimed to investigate the incidence and risk of endogenous endophthalmitis in patients with PLA compared with unaffected individuals by using a nationwide, population-based dataset. DESIGN: Retrospective, cohort study. PARTICIPANTS AND CONTROLS: This study used data sourced from Taiwan's National Health Insurance Research Database. In total, 12 727 patients with PLA were included in the study group and 63 635 matched subjects were randomly extracted as a comparison group. METHODS: Stratified Cox proportional hazards regressions were performed to assess the effect of PLA on the hazard of developing endogenous endophthalmitis. MAIN OUTCOME MEASURES: The incidence and risk of endogenous endophthalmitis between the study group and comparison group. RESULTS: Of the total sample, 148 subjects (0.10%) were diagnosed with endophthalmitis during the 1-year follow-up period. Endophthalmitis was found in 106 patients (0.84%) with PLA and 42 comparison patients (0.07%). After adjusting for patient monthly income, geographic location, and urbanization level, those suffering from PLA were found to have a greater likelihood of developing endophthalmitis during the 1-year follow-up period than comparison patients (hazard ratio [HR], 12.83; 95% confidence interval, 8.94-18.41). Stratification did not reveal any large differences in the adjusted HRs for endophthalmitis between PLA patients suffering from diabetes and those in whom diabetes was absent. We further analyzed the etiology of cases with endogenous endophthalmitis in this investigation and found Klebsiella pneumonia to be the causative organism among 75.5% of the cases but only 33.4% of the comparison group. CONCLUSIONS: We found that the incidence and risk of developing endophthalmitis was significantly higher among patients with PLA compared with matched controls irrespective of diabetes status.


Asunto(s)
Endoftalmitis/etiología , Absceso Piógeno Hepático/complicaciones , Adolescente , Adulto , Anciano , Bases de Datos Factuales , Endoftalmitis/microbiología , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/aislamiento & purificación , Absceso Piógeno Hepático/microbiología , Masculino , Persona de Mediana Edad , Programas Nacionales de Salud/estadística & datos numéricos , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Factores de Riesgo , Taiwán , Adulto Joven
16.
Eur J Gastroenterol Hepatol ; 24(10): 1234-7, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22713510

RESUMEN

Multidrug-resistant infections represent an increasing problem in the management of hospitalized patients worldwide. With respect to Gram-negative infections, carbapenems are an important antimicrobial class for the treatment of infections caused by extended-spectrum beta lactamase producers enterobacteriaceae. However, the emergence of novel ß-lactamases with direct carbapenem-hydrolyzing activity has contributed toward an increased prevalence of carbapenem-resistant enterobacteriaceae. Recent reports have described the spread of carbapenemase-producing Klebsiella pneumoniae across the world. There are very few existing agents that can be used against these pathogens and there are limited options on the horizon. In recent years, the epidemiology of bacterial strains involved in the pathogenesis of spontaneous bacterial peritonitis has also been changing rapidly. In this setting, we report the first case of nosocomial spontaneous bacterial peritonitis due to carbapenemase-producing K. pneumoniae.


Asunto(s)
Carbapenémicos/uso terapéutico , Hígado Graso/complicaciones , Infecciones por Klebsiella/complicaciones , Klebsiella pneumoniae/efectos de los fármacos , Peritonitis/microbiología , Resistencia betalactámica , Carbapenémicos/farmacología , Infección Hospitalaria/diagnóstico , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Humanos , Infecciones por Klebsiella/diagnóstico , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/aislamiento & purificación , Klebsiella pneumoniae/metabolismo , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Peritonitis/tratamiento farmacológico
17.
Rev Med Chir Soc Med Nat Iasi ; 115(3): 769-75, 2011.
Artículo en Rumano | MEDLINE | ID: mdl-22046785

RESUMEN

UNLABELLED: Infections in diabetic patient remains an important cause of morbidity and mortality, triggering and maintaining a prolonged metabolic imbalance. Emergence of extented spectrum beta-lactmase (ESBL) in Escherichia coli and Klebsiella pneumoniae is a major concern, because of the atypical manner infection acts in this group of imunodepressed patients and also for the limited therapeutic solutions. For this reason we have evaluated the profile of antimicrobial resistance of these pathogens in both diabetic and non diabetic patients. MATERIAL AND METHOD: The aim of this study was to evaluate, in a retrospective case control study, the antibiotic susceptibility pattern in isolates of E. coli and Klebsiella spp. from different biological products in 49 diabetics and 150 non-diabetics admitted in The Clinical Hospital of Infectious Diseases Iasi over a period of two years. RESULTS: Most of strains of E. coli and Klebsiella spp. ESBL positive were found in uroculture. Significant differences in E. coli resistance rate between diabetics and nondiabetics were noted for amoxicillin-clavulanic acid and ciprofloxacin (31,4% vs.13,98%, p=0,04, respectively 52,9% vs. 24,46%, p=0,004). More isolates of ESBL positive K. pneumoniae were found in diabetic patients (50% vs. 24%). Ciprofloxacin resistance of K. pneumoniae was significantly higher in diabetics (75% vs 39%; p=0,05). There was no resistance in E. coli and K. pneumoniae isolates to imipenem in the diabetic group. CONCLUSIONS: The high resistance rate to quinolones and 3rd generation cefalosporins limits their use for the treatment of Escherichia coli and K. pneumoniae infections. Other alternatives for empiric therapy in community and nosocomial-acquired infections in diabetic patient remains carbapenems, aminoglycosides and colimycin.


Asunto(s)
Antibacterianos/uso terapéutico , Complicaciones de la Diabetes/tratamiento farmacológico , Infecciones por Escherichia coli/tratamiento farmacológico , Escherichia coli/efectos de los fármacos , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Aminoglicósidos/uso terapéutico , Amoxicilina/uso terapéutico , Antiinfecciosos/uso terapéutico , Carbapenémicos/uso terapéutico , Estudios de Casos y Controles , Cefalosporinas/uso terapéutico , Niño , Preescolar , Ciprofloxacina/uso terapéutico , Ácido Clavulánico/uso terapéutico , Colistina/uso terapéutico , Farmacorresistencia Bacteriana , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/complicaciones , Femenino , Humanos , Imipenem/uso terapéutico , Lactante , Infecciones por Klebsiella/complicaciones , Klebsiella pneumoniae/aislamiento & purificación , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Quinolonas/uso terapéutico , Resultado del Tratamiento
18.
Infez Med ; 19(4): 224-34, 2011 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-22212161

RESUMEN

A novel type of carbapenemase, New Delhi metallo beta-lactamase 1 (NDM 1), was first identified in 2008 in two Enterobacteriacea isolates, both recovered from a Swedish patient transferred from India. The emergence of NDM 1 is now reported from all continents, often in patients with a history of travel or hospitalization in the Indian subcontinent. The NDM 1 producing Gram-negative bacteria are mainly Enterobacteriaceae, which can cause colonization or fatal infections, with worrying antimicrobial susceptibility profiles: some isolates have developed resistance to practically all available antibiotics. Is the NDM-1 the super-bug? Are we in the post-antibiotic era? This review is a summary of currently available knowledge of NDM-1 that draws attention to future antimicrobial resistance scenarios.


Asunto(s)
Absceso/tratamiento farmacológico , Antibacterianos/uso terapéutico , Colistina/uso terapéutico , Complicaciones de la Diabetes , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , beta-Lactamasas/metabolismo , Absceso/microbiología , Antibacterianos/farmacología , Nalgas , Colistina/farmacología , Farmacorresistencia Bacteriana Múltiple , Humanos , India , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/enzimología , Klebsiella pneumoniae/aislamiento & purificación , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Suecia , Viaje , Resultado del Tratamiento , beta-Lactamasas/efectos de los fármacos
19.
J Med Microbiol ; 59(Pt 11): 1383-1386, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20688947
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA